Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,058 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Takeda Clear all
Terminated Phase 2 Interventional Results available

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

NCT02993783
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Early Phase 1 Interventional Results available

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

NCT02630030
View directory record Official record
Conditions
Glioblastoma
Interventions
Ixazomib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

NCT00242177
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTOS (Pioglitazone)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Blood Pressure

NCT01496469
View directory record Official record
Conditions
Hypertension
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Foley, Alabama • Buena Park, California • Carmichael, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

NCT02916771
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT04419649
View directory record Official record
Conditions
Myelodysplastic Syndromes, Cytopenia
Interventions
Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

NCT06470828
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
Oveporexton, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00847626
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Chlorthalidone, Azilsartan medoxomil
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
84
States / cities
Birmingham, Alabama • Columbiana, Alabama • Tuscaloosa, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.

NCT00671294
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon and Placebo (9 possible combinations total)
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Hot Springs, Arkansas • Irvine, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

NCT01259726
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
VP20621, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Modesto, California • Palm Desert, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

NCT02574286
View directory record Official record
Conditions
Gaucher Disease
Interventions
Velaglucerase alfa, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 17, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

NCT02202759
View directory record Official record
Conditions
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
Interventions
MLN0264
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Aurora, Colorado • St. Petersburg, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Open Label Extension Study of PREOS

NCT00172133
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 (drug)
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Not listed Phase 2 Interventional

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

NCT05764993
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy
Biological · Other
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

NCT03401671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Active, not recruiting No phase listed Observational

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934
View directory record Official record
Conditions
Hemophilia A
Interventions
ADYNOVI/ADYNOVATE
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 17, 2026, 2:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

NCT00776555
View directory record Official record
Conditions
Healthy
Interventions
Lisdexamfetamine Dimesylate, Racemic mixture of dextroamphetamine and lisdexamfetamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 2:48 PM EDT
Completed No phase listed Observational

Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)

NCT00919152
View directory record Official record
Conditions
Stress Ulcer Prophylaxis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 17, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 17, 2026, 2:48 PM EDT